---
schema_version: "secwatch.filing_event.v1"
accession: "0001601485-24-000009"
form_type: "8-K"
ticker: "ELTX"
cik: "0001601485"
company_name: "Elicio Therapeutics, Inc."
filed_at: "2024-01-17T23:59:59+00:00"
generated_at: "2026-06-06T22:34:48.314966+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Elicio presents ELI-002 7P Phase 1/2 trial design at ASCO GI; Phase 1A complete, Phase 2 enrolling

## Summary
- Phase 1A completed with no dose-limiting toxicities; Phase 2 randomized 2:1 study enrolling PDAC patients.
- ELI-002 7P targets seven KRAS mutations driving 25% of solid tumors using AMP lymph node-targeting platform.
- First patient dosed in randomized Phase 2 cohort comparing ELI-002 7P to standard of care (observation).
- Previous 2-peptide formulation published in Nature Medicine showed tumor biomarker reduction and reduced risk of relapse/death.

## SEC filing metadata
- accession: 0001601485-24-000009
- form_type: 8-K
- ticker: ELTX
- cik: 0001601485
- company_name: Elicio Therapeutics, Inc.
- filed_at: 2024-01-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1601485/000160148524000009/0001601485-24-000009-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1601485/000160148524000009/angn-20240117.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001601485-24-000009
- JSON: https://secwatch.observer/filing/0001601485-24-000009.json
- Plain text: https://secwatch.observer/filing/0001601485-24-000009.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.